Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Anticipate generic drug launch
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
|Title:||Method of providing sustained analgesia with buprenorphine|
|Abstract:||A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.|
|Inventor(s):||Reder; Robert F. (Greenwich, CT), Goldenheim; Paul D. (Wilton, CT), Kaiko; Robert F. (Weston, CT)|
|Assignee:||Euro-Celtique, S.A. (Luxembourg, LU)|
Patent Claim Types:|
see list of patent claims
Field: Medical technology
Back Citations: 24th percentile
Forward Citations: 7th percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.